<DOC>
	<DOCNO>NCT03087058</DOCNO>
	<brief_summary>The purpose study evaluate change serum ( blood ) potassium level start treatment Day 14 , patiromer administer different dos , daily , child 2 - &lt; 18 year age chronic kidney disease ( CKD ) hyperkalemia ( much potassium blood ) . Another purpose study evaluate safety tolerability patiromer child 2 - &lt; 18 year age CKD hyperkalemia .</brief_summary>
	<brief_title>Pharmacodynamic &amp; Safety Patiromer Children &amp; Adolescents ( 2- &lt; 18 Yrs ) With Chronic Kidney Disease Hyperkalemia</brief_title>
	<detailed_description>Up 54 subject , 2 - &lt; 18 year age CKD ( estimate glomerular filtration rate [ eGFR ] &lt; 60 mL/min/1.73 m2 ) hyperkalemia ( two potassium measurement 5.1 &lt; 6.5 mEq/L perform separate day ) enrol open-label , multiple-dose , Phase 2 study . The study include two treatment phase : Pharmacodynamic ( PD ; drug effect potassium ) / Dose Finding Phase consist initial 14-day dose find period follow 5.5-month Long-Term Treatment Phase total study participation duration individual subject 6.5 month ( include 2 week follow period ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>Written assent ( applicable ) write informed consent legally authorize representative provide prior participation study Age 2 &lt; 18 year old CKD define eGFR &lt; 60 mL/min/1.73m2 include renal transplant , peritoneal dialysis Two potassium measurement 5.1 &lt; 6.5 mEq/L perform separate day In opinion study doctor , expect require treatment hyperkalemia least 6 month If take reninangiotensinaldosterone system inhibitor ( RAASi ) beta blocker diuretic medication , must stable dose least 28 day prior Screening Negative pregnancy test female childbearing potential False elevation blood potassium ( pseudohyperkalemia ) due hemolysis ( break blood cell ) abnormally high count blood cell Screening Evidence potassiumrelated electrocardiogram ( ECG ) change Screening Any follow kidney condition : hemodialysis , renal artery stenosis , acute kidney injury history acute renal insufficiency past 3 month Severe disorder stomach intestine include surgery Increased liver enzymes ( ALT , AST &gt; 3 time upper limit normal ) Screening Active cancer , currently cancer treatment history cancer past 2 year ( except nonmelanoma skin cancer ) Have heart liver transplant , anticipate need transplant study treatment period include schedule kidney transplant . ( Note : patient currently kidney transplant wait list exclude unless identify donor ) . Alcohol abuse substance use disorder within 1 year Screening Subjects currently treat take one follow medication ( include resin ) 7 day prior Screening : sodium calcium polystyrene sulfonate , drospirenone Use certain medication affect blood potassium level dose stable least 14 day prior Screening dos anticipate change 14day PD / Dose Finding Phase Use investigational product within 30 day screen within 5 halflives , whichever long Known hypersensitivity patiromer component In opinion Investigator , medical condition , uncontrolled systemic disease , serious intercurrent illness would significantly decrease study compliance jeopardize safety subject potentially affect quality data</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treatment Hyperkalemia</keyword>
	<keyword>Hyperkalemia</keyword>
	<keyword>Potassium</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>